Caffeic acid 咖啡酸,98.71%
产品编号:Bellancom-N0172| CAS NO:331-39-5| 分子式:C9H8O4| 分子量:180.16
Caffeic acid 是 TRPV1 离子通道和 5-脂氧合酶 (5-LO) 的抑制剂。咖啡酸以非竞争性的方式抑制5-脂氧合酶。咖啡酸及其甲酯对前列腺素合成酶活性没有任何抑制作用,至少在5 × 10(-4) M以上,但在较高剂量时反而有刺激作用。咖啡酸已被证明在高剂量时能抑制血小板中的花生四烯酸代谢。它被观察到在高剂量下刺激前列腺素的合成。咖啡酸是GST、ODC、Tyk和黄嘌呤氧化酶的抑制剂。咖啡酸抑制白三烯的合成,白三烯参与免疫调节、炎症和过敏。咖啡酸抑制Cu2+诱导的低密度脂蛋白氧化。
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Caffeic acid 咖啡酸
产品介绍 | Caffeic acid 是 TRPV1 离子通道和 5-脂氧合酶 (5-LO) 的抑制剂。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | Caffeic acid is an inhibitor of both TRPV1 ion channel and 5-Lipoxygenase (5-LO). | ||||||||||||||||
体外研究 |
Caffeic acid has inhibitory effects on histamine-induced responses and the inhibitory effect of Caffeic acid is gradually increased when the concentration used for pretreatment is increased from 0.1 to 1 mM, similar to typical dose-dependent responses. Pretreatment of HEK293T-TRPV1 cells with 1 mM Caffeic acid results in significant inhibition of capsaicin-induced responses. When lower concentration of Caffeic acid is used, the inhibitory effect for capsaicin-induced responses is less evident. Calcium imaging experiments show that Caffeic acid incubation results in significant inhibition in histamine-sensitive dorsal root ganglion (DRG) neurons. Pretreatment with Caffeic acid (1 mM) results in a significant decrease in the percentage of responsive DRG neurons to histamine application from 12.5% to 2.1%. Pretreatment with 1 mM Caffeic acid dramatically blocks the allylisothiocyanate (AITC)-induced intracellular calcium increase in TRPA1-expressing cells. Caffeic acid is also able to block the AITC-induced activation of TRPA1. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
Mice pretreated with Caffeic acid (500 mg/kg) exhibit significantly less histamine-induced scratching (30.50±10.87 bouts/1 h, n=6). It is further found that the lower dose of Caffeic acid (100 mg/kg) is not significantly effective in terms of anti-scratching effects in histamine-induced scratching, although there appears to be a tendency of reduction (49.40±12.35 bouts/1 h, n=5). The chloroquine induced scratching is significantly inhibited by pretreatment with 500 mg/kg of Caffeic acid (161.6±31.42 bouts/1 h, n=5).Caffeic acid significantly reduces the expression of 5-LO mRNA (P<0.01) dose-dependently in hippocampus. Compare with the ischemia-reperfusion (I/R) non-treated group, 5-LO protein expression is significantly reduced in the I/R-Caffeic acid group (P<0.05 or P<0.01), especially in the I/R-Caffeic acid group (50 mg/kg). Compare with the I/R non-treated group, the latency to find platform is significantly shortened in low- and high-dose Caffeic acid groups, the shortened platform latency is most evident in the I/R- Caffeic acid group (50 mg/kg) (P<0.01). In the low-dose Caffeic acid group, cell injury is still marked, the pyknosis ratio is (63.6±2.8)%, whereas in the high-dose Caffeic acid group, hippocampal neuron karyopyknosis is significantly reduced and the pyknosis ratio is (13.3±3.0)%. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
Mice pretreated with Caffeic acid (500 mg/kg) exhibit significantly less histamine-induced scratching (30.50±10.87 bouts/1 h, n=6). It is further found that the lower dose of Caffeic acid (100 mg/kg) is not significantly effective in terms of anti-scratching effects in histamine-induced scratching, although there appears to be a tendency of reduction (49.40±12.35 bouts/1 h, n=5). The chloroquine induced scratching is significantly inhibited by pretreatment with 500 mg/kg of Caffeic acid (161.6±31.42 bouts/1 h, n=5).Caffeic acid significantly reduces the expression of 5-LO mRNA (P<0.01) dose-dependently in hippocampus. Compare with the ischemia-reperfusion (I/R) non-treated group, 5-LO protein expression is significantly reduced in the I/R-Caffeic acid group (P<0.05 or P<0.01), especially in the I/R-Caffeic acid group (50 mg/kg). Compare with the I/R non-treated group, the latency to find platform is significantly shortened in low- and high-dose Caffeic acid groups, the shortened platform latency is most evident in the I/R- Caffeic acid group (50 mg/kg) (P<0.01). In the low-dose Caffeic acid group, cell injury is still marked, the pyknosis ratio is (63.6±2.8)%, whereas in the high-dose Caffeic acid group, hippocampal neuron karyopyknosis is significantly reduced and the pyknosis ratio is (13.3±3.0)%. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (555.06 mM; Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic) (insoluble) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |
|
符号 |
![]() ![]() GHS07, GHS08 |
---|---|
信号词 | Warning |
危害声明 | H315-H319-H335-H351-H361 |
警示性声明 | P261-P281-P305 + P351 + P338 |
个人防护装备 | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
危害码 (欧洲) | Xn:Harmful |
风险声明 (欧洲) | R36/37/38;R40 |
安全声明 (欧洲) | S26-S36/37/39 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | GD8950000 |
海关编码 | 2942000000 |
产品名: | Caffeic acid |
CAS号: | 331-39-5 |
制造商/供应商: | 西域试剂 网站:www.hzbp.cn 邮件:13911702513@139.com |
2. 合成/成分数据
产品名: | Caffeic acid |
分子式: | C9H8O4 |
分子量: | 180.16 |
3. 急救措施
吸入后: | 如果吸入,移至空气新鲜处,如果呼吸困难,给输氧,如呼吸停止,给予人工呼吸。 |
皮肤接触后: | 用大量的水冲洗,移除污染的衣服和鞋子。 |
眼睛接触后: | 检查并取下隐形眼镜,并用大量的水冲洗;呼叫医生。 |
吞食后: | 如果吞食,用大量纯净水漱口;呼叫医生。 |
4. 消防措施
适当的灭火剂: | 雾状水,二氧化碳,干粉或泡沫。 |
防护设备: | 穿戴自给式呼吸器和防护服,以防止与皮肤和眼睛接触。 |
5. 泄漏应急处理
安全防范措施: | 封锁泄漏区域;穿戴自给式呼吸器,防护服和厚橡胶手套。 |
清洁/收集措施: | 使用液体粘合原料(硅藻土,通用粘合剂)吸取精细粉末; 使用酒精擦洗表面和设备除去污渍; 根据第11条处理被污染的材料。 |
6. 处理和储存
安全处理说明: | 避免吸入和接触皮肤,眼睛及衣物;材料可能略微具有刺激性。 |
储存: |
粉末型式 -20°C 3年;4°C 2年 溶于溶剂 -80°C 6个月;-20°C 1个月 |
7. 接触控制和个人防护
呼吸设备: | NIOSH / MSHA认可的呼吸器。 |
双手保护: | 耐化学腐蚀的橡胶手套。 |
眼睛防护: | 化学安全护目镜。 |
8. 稳定性和反应活性
稳定性: | 按照说明存储是稳定的;避免强氧化剂。 |
热分解/其他要避免的情况: | 避免光和热。 |
9. 毒性资料
急性毒性: | 无可用资料。 |
主要刺激性影响: | 无可用资料。 |
在皮肤上: | 无可用资料。 |
对眼睛: | 无可用资料;可能具有刺激性。 |
10. 生态资料
一般注意事项: | 无可用资料。 |
11. 废弃处置
按照所在国家,省份,县市和地方的法规处置。 |
12. 运输信息
正确的运输名称: | 无 |
非危险品运输: | 这种物质被视为非危险品运输。 |
13. 法规信息
尚未有针对此产品作出的化学安全性评估。 |
14. 其他信息
这种化学品仅供受过训练的,有经验的研究人员在穿戴适当装备和授权允许的情况下进行操作处理。以上信息基于我们目前的知识被认为是正确的,但只适用于作为有经验人员的指导。请咨询您自己的安全顾问,并遵守当地和国家的安全法规。在任何其他没有被警告的情况下,并不意味着绝对没有危险存在。西域生物技术不承担任何使用这种化学品所造成的损害和责任。2023 西域生物技术版权所有。 |
上游产品 7 | |
---|---|
下游产品 10 | |

匹配竞争对手的价格

效率为先

专业经验 贴心服务

50000+库存